Updated:
RV Invest
RVI is a VC fund of Vetter Pharma family office. Our mission is to support innovations that improve patients‘ life. We engage early and stand alongside...
RV Invest
RVI is a VC fund of Vetter Pharma family office. Our mission is to support innovations that improve patients‘ life. We engage early and stand alongside founders and researchers to bring outstanding ideas to the market. We invest in highly differentiated technical solutions that can become future standards of care.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Germany
City
Ravensburg
Corporate office
Banneggstrasse 57, 88214 Ravensburg, Germany
Principals
Aleksei Zeifman
Investment Team
Nicholas H. Vetter
Investment Team
Timo Köhler
Investment Team
Carla Benichou
Investment Team
Lu Zheng
Investment Team
Susanne Schaffert
Investment Team
Patrick Lally
Investment Team
Alexey A. Lugovskoy
Investment Team
Sector focus
Frequently asked questions
Who makes investment decisions at RV Invest?
The investment team is led by Nicholas H. Vetter and Aleksei Zeifman. Vetter brings operational biotech leadership and direct ties to Vetter Pharma, while Zeifman contributed a decade of investing experience from funds including RBV Capital and a corporate venture role at SCOR. The broader team includes senior figures such as former Novartis Oncology President Susanne Schaffert and former OrbiMed and Fortress investor Patrick Lally, indicating collective decision-making rather than a single CIO model.
What is RV Invest’s relationship with Vetter Pharma?
Nicholas H. Vetter, a member of the third generation of the Vetter Pharma family, is part of the RV Invest investment team. Vetter Pharma is a contract development and manufacturing organization that specializes in aseptic filling and packaging of injectable drugs. RV Invest’s strategy does not require portfolio companies to use Vetter Pharma’s services, but the firm’s team has deep knowledge of pharmaceutical manufacturing and commercialization pathways.
Does RV Invest lead rounds in its portfolio companies?
RV Invest participates in early-stage financing rounds, though its website does not disclose whether it acts as lead investor. The firm has been involved in a syndicate that raised a $125 million Series B for Diagonal Therapeutics and an €8 million seed round for Akribion Therapeutics. The firm typically co-invests alongside specialist life sciences funds and crossover investors.
What is the geographic focus of RV Invest’s portfolio?
RV Invest invests across Europe and the United States. Current portfolio companies are based in Germany, Sweden, the United Kingdom, and the US. The firm has a particular concentration in German and Nordic early-stage biotech, consistent with the locations of its founding team and its headquarters in Ravensburg.
What types of therapeutic modalities does RV Invest target?
RV Invest focuses on platform technologies that produce novel therapeutic modalities rather than traditional small-molecule drug development. The portfolio includes agonist antibodies, in vivo cell reprogramming, RNA-guided cell depletion, cell therapy for rare diseases, radiopharmaceuticals, and epigenetic engineering. The firm does not appear to invest in digital health, medical devices, or diagnostics.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: